Product Name: Fezolinetant API
Chemical Name: 5-[(2R)-2-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Molecular Formula: C18H17F2N5O
Molecular Weight: 357.36 g/mol
CAS Number: 1637780-07-5
Therapeutic Category: Neurokinin 3 (NK3) Receptor Antagonist
Indication: Fezolinetant is an investigational drug primarily developed for the treatment of menopausal vasomotor symptoms (VMS), commonly known as hot flashes. It works by blocking the action of neurokinin B (NKB) on the NK3 receptor in the thermoregulatory center of the hypothalamus, thereby reducing the frequency and severity of hot flashes.
Mechanism of Action: Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. By inhibiting the binding of NKB to the NK3 receptor, it modulates the activity of the KNDy (kisspeptin, neurokinin B, and dynorphin) neurons in the hypothalamus, which play a key role in the regulation of body temperature and the occurrence of vasomotor symptoms.
Pharmacokinetics:
Absorption: Fezolinetant is well-absorbed following oral administration.
Distribution: It exhibits a moderate volume of distribution, indicating good tissue penetration.
Metabolism: Fezolinetant is primarily metabolized by the liver via cytochrome P450 enzymes.
Excretion: The drug and its metabolites are mainly excreted in the urine.
Storage Conditions: Fezolinetant API should be stored in a dry place, protected from light and moisture.
Stability: Fezolinetant is stable under recommended storage conditions. It should be protected from extreme temperatures and humidity to maintain its stability and efficacy.
Regulatory Status: Fezolinetant is currently under clinical development and has not yet received approval for commercial use. It is being evaluated in various clinical trials to assess its safety and efficacy in treating menopausal vasomotor symptoms.
Packaging: Fezolinetant API is supplied in sealed, light-resistant containers to ensure product integrity. The packaging is designed to protect the API from environmental factors that could compromise its quality.
Quality Standards: Fezolinetant API is manufactured in compliance with current Good Manufacturing Practices (cGMP) and meets stringent quality control standards to ensure its purity, potency, and consistency.
Applications: Fezolinetant API is intended for use in the development and production of pharmaceutical formulations aimed at treating menopausal vasomotor symptoms. It is suitable for use in both clinical trials and commercial pharmaceutical manufacturing.
Note: This product is intended for research and development purposes only. It is not for human use unless specified by regulatory authorities.
Product Name: Fezolinetant API
Chemical Name: 5-[(2R)-2-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Molecular Formula: C18H17F2N5O
Molecular Weight: 357.36 g/mol
CAS Number: 1637780-07-5
Therapeutic Category: Neurokinin 3 (NK3) Receptor Antagonist
Indication: Fezolinetant is an investigational drug primarily developed for the treatment of menopausal vasomotor symptoms (VMS), commonly known as hot flashes. It works by blocking the action of neurokinin B (NKB) on the NK3 receptor in the thermoregulatory center of the hypothalamus, thereby reducing the frequency and severity of hot flashes.
Mechanism of Action: Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. By inhibiting the binding of NKB to the NK3 receptor, it modulates the activity of the KNDy (kisspeptin, neurokinin B, and dynorphin) neurons in the hypothalamus, which play a key role in the regulation of body temperature and the occurrence of vasomotor symptoms.
Pharmacokinetics:
Absorption: Fezolinetant is well-absorbed following oral administration.
Distribution: It exhibits a moderate volume of distribution, indicating good tissue penetration.
Metabolism: Fezolinetant is primarily metabolized by the liver via cytochrome P450 enzymes.
Excretion: The drug and its metabolites are mainly excreted in the urine.
Storage Conditions: Fezolinetant API should be stored in a dry place, protected from light and moisture.
Stability: Fezolinetant is stable under recommended storage conditions. It should be protected from extreme temperatures and humidity to maintain its stability and efficacy.
Regulatory Status: Fezolinetant is currently under clinical development and has not yet received approval for commercial use. It is being evaluated in various clinical trials to assess its safety and efficacy in treating menopausal vasomotor symptoms.
Packaging: Fezolinetant API is supplied in sealed, light-resistant containers to ensure product integrity. The packaging is designed to protect the API from environmental factors that could compromise its quality.
Quality Standards: Fezolinetant API is manufactured in compliance with current Good Manufacturing Practices (cGMP) and meets stringent quality control standards to ensure its purity, potency, and consistency.
Applications: Fezolinetant API is intended for use in the development and production of pharmaceutical formulations aimed at treating menopausal vasomotor symptoms. It is suitable for use in both clinical trials and commercial pharmaceutical manufacturing.
Note: This product is intended for research and development purposes only. It is not for human use unless specified by regulatory authorities.
